PLX-4720

Catalog No.S1152

PLX-4720 Chemical Structure

Molecular Weight(MW): 413.83

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

10 Customer Reviews

  • Combinatorial knockdown of NF1 and C-RAF abrogates NF1-mediated resistance to B-RAF inhibition at the level of ERK phosphorylation. A375 cells were infected with NF1 shRNA and treated with either DMSO or PLX4720 for 16 h. Cell lysates were analyzed for the indicated proteins.

    Cancer Discov 2013 3, 350-62. PLX-4720 purchased from Selleck.

    Most of the resistant cells had higher levels of DCT compared with the parental cells. Cells were stained with a fluorescent-labeled DCT antibody (green) and counterstained with DAPI (blue).

    Genome Res, 2018, 28(9):1353-1363. PLX-4720 purchased from Selleck.

  • RAF inhibitors induce dimer formation between KSR and RAF, and activate KSR by CRAF. (A) GDC0879 but not PLX4720 induces BRAF/CRAF dimers. Cells overexpressing myc-CRAF and BRAF were treated with drug for 1 h and CRAF immunoprecipitates were immunoblotted for BRAF and CRAF (epitope tagged with myc). (B) GDC0879 but not PLX4720 enhances KSR/BRAF complexes. KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and BRAF after treatment with the indicated drug for 1 h and immunoblotted using antibodies to BRAF. (C) Both GDC0879 and PLX4720 induce KSR/CRAF complexes.KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and myc-CRAF after treatment with the indicated drug for 1 h and immunoblotted for CRAF using myc antibodies. (D and E) Requirement of KSR for drug-induced ERK activation. Lysates fromwild-type and KSR deficient fibroblasts, transfected with RASV12, were treated with the indicated doses of either GDC-0879 (D) or PLX4720 (E) for 1 h. Lysates were immunoblotted for phospho-ERK1 and 2, ERK2, and RASV12. (F) KSR and CRAF cooperate to activate MEK. Cells expressing the indicated constructs were treated with a 50 μM PLX4720 for 2 h before cell lysates were prepared and analyzed for pMEK by immunoblotting. CRAF(TM) refers to the T421M gatekeeper mutant that cannot bind to the drug(4). (G) KSR in vitro kinase reactions. Cells were cotransfected with WT or ATP binding deficient KSR and CRAF and immunoprecipitates prepared after cells were treated with an activating dose of PLX (10 μM) for 1 h. KSR immunoprecipitates were prepared, pretreated with 50 uM PLX4720 to inhibit coprecipitating RAF activity, and then tested for kinase activity using purified MEK. MEK phosphorylation was detected using a pMEK specific antibody.

    Proc Natl Acad Sci USA 2011 108, 6067-6072. PLX-4720 purchased from Selleck.

    (D)Melanoma cell lines were treated with 0.5 uM Pi-103 and/or 2 uM PLX4720 for 4 h. Samples were analyzed by Western blotting for the indicated proteins. β-Actin served as a loading control. (E) Melanoma cell lines were treated with a dilution series of Pi-103 either alone or in combination with the BRAFV600E inhibitor PLX4720 at a concentration of 3 uM (D10) or 1 uM (453A0) for 3 d. Total cell numbers were determined with a cell titer blue assay. The Y-axis represents the percentage of living cells.

    Genes Dev 2012 26, 1055-69. PLX-4720 purchased from Selleck.

  • PTEN predicts for PLX4720-induced apoptosis. A, basal PTEN and phospho-AKT(pAKT; S473, T308) expression in PTENt (WM164, 451Lu, SK-mel-28, WM983A, WM35, WM51) and PTEN (WM239A, WM266-4, WM793, M233, WM9, 1205Lu) melanoma cell lines. B, MTT assay of PTENt (gray)-expressing versus PTEN (black) cell lines. C, PTENt cells are more sensitive than PTEN cells to PLX4720-mediated apoptosis. Cells treated for 48 hours with 3 or 10 μmol/L PLX4720 before being stained for TMRM and Annexin-V. Apoptosis was measured by flow cytometry. Data shows mean SE mean of 3 independent experiments.*, PTENt cohort significantly different from PTEN cohort(P < 0.05).

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

    Loss of PTEN is associated with PI3K/AKT signaling following BRAF inhibition. A, PTENt (WM35, WM164, WM983A) and PTEN (M233, WM9,WM793, 1205Lu) cells were treated with PLX4720 (24 hours: 0.03-3 μmol/L) and probed for phospho-PDK1 (pPDK1), total PDK1, phospho-AKT (pAKT), total AKT (tAKT), phospho-S6 (pS6), and total S6. Numbers indicate relative intensity of pPDK1 normalized to PDK1 and pAKT normalized to tAKT. B, PLX4720 increases pAKT following PTEN knockdown. WM35 cells were incubated with nontargeting siRNA (NT) or 2 different PTEN-specific siRNA's (PTEN) before treatment with either vehicle or PLX4720 (3 μmol/L). C, siRNA knockdown of BRAF increases pAKT in melanoma cell lines that are PTEN. WM164 (PTENt) and WM793 (PTEN) cells were incubated with lipofectamine alone (L), nontargeting siRNA (NT), or BRAF-specific siRNA (BRAF). Protein was extracted, resolved, and probed for BRAF, pAKT, total AKT, and GAPDH.

     

     

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

  • Dual PI3K/BRAF inhibition upregulates BIM and enhances apoptosis in PTEN cells. A, left, Western blot of 1205Lu cells treated with PLX4720 (3 μmol/L, 48 hours), the PI3K inhibitor GDC-0941 (3 μmol/L, 48 hours), or both drugs in combination (PtG); right, immunofluorescence staining of BIM (green) and DAPI (blue) in PTEN cells following PLX4720 treatment (3 μmol/L, 48 hours), the PI3K inhibitor LY294002 (10 μmol/L, 48 hours), or both drugs in combination (PLXtLY). B, left, immunofluorescence staining of PTEN 1205Lu following combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48hours) increases nuclear localization of FOXO3a (green). DAPI is shown in blue. Magnification 40. Right, combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48 hours) increases PTEN WM793 BIM mRNA levels to those observed with single BRAF inhibition (3 μmol/L PLX4720, 48 hours) in the PTENt WM35. C, PTEN cells were treated with PLX4720 (3 μmol/L, 48 hours), GDC-0941 (3 μmol/L, 48hours), or a combination of the 2 drugs (3Pt3G) before Annexin-V staining was analyzed by flow cytometry (*, P < 0.05 between the drug combination and each inhibitor alone). D, combined BRAF/PI3K inhibitor treatment blocks the escape of 1205Lu cells (PTEN) from therapy. Spheroids of 1205Lu cells were treated with either PLX4720 alone (3 and 10 μmol/L: data shows 3 μmol/L), LY294002 (10 μmol/L) alone or a combination of the 2 drugs for 72 hours. In other studies, spheroids were treated with drugs for 72 hours and then allowed to recover for 120 hours. Micrograph shows viability staining (green ?live cells, red ?dead cells). Magnification 10.

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

    LC-MRM identifies differential regulation of BIM in PTENt and PTEN cell lines following PLX4720 treatment. A, representative LC-MRM data showing the fold changes in the expression of Bak, Bax, Bcl-2, Bcl-w, Bcl-xL, BID, BIM, Bok, and Mcl-1 over internal standard in the WM164 (PTENt) and 1205Lu (PTEN) cell lines following treatment with PLX4720 (10 μmol/L, 0-48 hours). Statistical analysis of BIM fold change in PTEN versus PTENt. *, P < 0.05. B, Western blot showing BIM expression following PLX4720 treatment (10 μmol/L, 0-48 hours) in PTEN (WM793, 1205Lu) and WM164 cell lines (PTENt). C, immunofluorescence staining, showing expression of BIM and DAPI staining of PTEN (M233, WM9, WM793, 1205Lu) and PTENt (WM35, WM164, WM983A) cells following PLX4720 treatment (3 μmol/L, 48 hours).D, Western blot showing BAD phosphorylation following treatment with PLX4720 (0-48 hours) in PTEN (WM793,1205Lu) and PTENt WM164. Annexin V binding following treatment with 3 or 10 μmol/L PLX4720 (48 hours) showing increased apoptosis in WM793 stably overexpressing WT BAD. *, P < 0.05.

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

  • B-RafV600E mutated melanoma line, SK-MEL-28, was treated with different doses of PLX-4720 for 4 h or 22 h.  Cell lysates were analyzed by Western blotting to determine the levels of phosphorylated MEK1/2 (pMEK1/2) and phosphorylated ERK1/2 (pERK1/2). MEK1/2 is the substrate of B-Raf while ERK1/2 is the substrate of MEK1/2.  Data show that phosphorylation of MEK1/2 and ERK1/2 was significantly inhibited by PLX-4720 treatment although total MEK1/2 or ERK1/2 protein levels were not affected. No pMEK1/2 or pERK1/2 signal was detected even after prolonged exposure, indicating that the inhibitor at 1 μM is very effective in blocking the constitutive kinase activity of B-RafV600E.  This data is consistent with the previous result demonstrating the effect of PLX-4720 in the B-RafV600E mutated melanoma line, A375 – Fig. 2A, Nature 464:431 (2010)

     

     

    Dr. Jong-In Park of Medical College of Wisconsin. PLX-4720 purchased from Selleck.

    A dose titration of PLX-4720 in A375 melanoma cells which possess a V600E B-Raf mutation.Effects of  increasing PLX-4720 dose on Erk phosphorylation and on tumor cell proliferation as determined by MTT  assay are shown.

     

     

    Dr. Daniel C.Cho of Harvard Medical School. PLX-4720 purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Targets
C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
BRK [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
6.7 nM 13 nM 130 nM 160 nM
In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-4475 NGXTXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e2UWlEPTB;MD6wO|Q2PyEQvF2= MmeyV2FPT0WU
EoL-1-cell MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nQfGlEPTB;MD6xOFE3PiEQvF2= MVzTRW5ITVJ?
C32 NI\PcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj6[JlKSzVyPUCuNVUyOzFizszN NVPISm1QW0GQR1XS
M14 M2XrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMkG3OVch|ryP MkTIV2FPT0WU
CP50-MEL-B NX3oVHo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMkm3PFQh|ryP M2D1fHNCVkeHUh?=
A101D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrnZ5VKSzVyPUCuN|I2QDlizszN MnTCV2FPT0WU
G-361 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDPXVJOUUN3ME2wMlM1PjN5IN88US=> MmHNV2FPT0WU
HT-144 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH3TWM2OD1yLkO2N|I6KM7:TR?= MlfUV2FPT0WU
ACN NVGyU4lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj2TWM2OD1yLkO4OFc4KM7:TR?= NFzsZYpUSU6JRWK=
COLO-829 M3;4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX1WYpKSzVyPUCuN|g6PjhizszN MVvTRW5ITVJ?
MEL-HO M3vuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17UXWlEPTB;MD60NVE4QSEQvF2= M2roXHNCVkeHUh?=
SH-4 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHJTWM2OD1yLkSxOFIzKM7:TR?= MknTV2FPT0WU
SK-MEL-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwNUG1Olgh|ryP M{XBWXNCVkeHUh?=
A375 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Xm[WlEPTB;MD62O|M2QSEQvF2= NUDxXWVNW0GQR1XS
MMAC-SF MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP1TWM2OD1yLk[4OlE1KM7:TR?= MWTTRW5ITVJ?
BHT-101 NYXyVFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\pTWM2OD1yLkewO|AzKM7:TR?= MmS4V2FPT0WU
K5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDLZWRKSzVyPUCuO|YyPDhizszN MYrTRW5ITVJ?
BV-173 M4DPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTVPWxKUUN3ME2wMlc6PjR2IN88US=> NH3xWYhUSU6JRWK=
RVH-421 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwOE[3PVYh|ryP MV\TRW5ITVJ?
HCC2218 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrrbFFFUUN3ME2wMlg4QDR2IN88US=> M2XyOXNCVkeHUh?=
WM-115 NGPUZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;sTWM2OD1yLki4OlkzKM7:TR?= MorTV2FPT0WU
SK-MEL-28 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrTXJBKSzVyPUGuNFQ2PjlizszN NWfISGl1W0GQR1XS
COLO-679 NFKxR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LwRWlEPTB;MT6xNFQ3PCEQvF2= MofnV2FPT0WU
MZ7-mel NHHHV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwMUS5OlMh|ryP MX\TRW5ITVJ?
SK-MEL-30 M2nQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP3V|ZKSzVyPUGuN|M{QDZizszN MVHTRW5ITVJ?
NCI-H209 NHHHRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLnTWM2OD1zLk[wPFYh|ryP MnWwV2FPT0WU
HTC-C3 NUi0[WhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwNk[yPVQh|ryP NEnHT3lUSU6JRWK=
KARPAS-45 NFT3bGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXiPJBKSzVyPUKuNFQ6PzhizszN NEnEfotUSU6JRWK=
NCI-SNU-5 NInJdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwMUG5Olkh|ryP NYP5fnN7W0GQR1XS
KP-4 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fTfmlEPTB;Mj6zNFc5PyEQvF2= Mmr5V2FPT0WU
PA-1 M3HTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\zTWM2OD1{LkeyOlc{KM7:TR?= MnPiV2FPT0WU
HuO-3N1 M4LvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17zbmlEPTB;Mj64O|k1PiEQvF2= MoC1V2FPT0WU
NCI-H358 NU\1V|FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfke4FKSzVyPUKuPVIzOzJizszN MYHTRW5ITVJ?
CTB-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG1dmV5UUN3ME2zMlQxOTd4IN88US=> Mn7wV2FPT0WU
697 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXjb|BKSzVyPUOuOVUzPjZizszN NUfBeJM{W0GQR1XS
CP66-MEL M2D0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnkXWtKSzVyPUSuNVU6OjdizszN M2fkcnNCVkeHUh?=
NB13 M{jnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF25[ZpKSzVyPUSuOFkyPzlizszN MWDTRW5ITVJ?
DBTRG-05MG NFX2XYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFftfI9KSzVyPUSuOVM{OjVizszN MmK3V2FPT0WU
A2058 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PrcGlEPTB;ND63NlE3PCEQvF2= MnfqV2FPT0WU
KG-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLscZdKSzVyPUSuO|M6ODhizszN NV3VUYhuW0GQR1XS
8305C M3PIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ja[2lEPTB;NT6xPFc{KM7:TR?= MWHTRW5ITVJ?
RPMI-7951 NW\oSpFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDzV|lKSzVyPUWuPFAzQDNizszN NWDVfZN3W0GQR1XS
CHL-1 NFPteppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TV[mlEPTB;NT65O|YxOyEQvF2= M2\pe3NCVkeHUh?=
TI-73 NVLtWGV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTZwMEC5NFIh|ryP MmHsV2FPT0WU
HT-1080 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P3b2lEPTB;Nj6xNFk1PiEQvF2= M1fmR3NCVkeHUh?=
ES5 NHLWfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTZwMUS5NlQh|ryP NGPsfo9USU6JRWK=
8-MG-BA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTZwMUixNlkh|ryP MlrlV2FPT0WU
NB7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HxPGlEPTB;Nj6yNVM4OyEQvF2= Ml;GV2FPT0WU
H4 NY\oUHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3lO45KSzVyPU[uNlI1QTNizszN NH\tT41USU6JRWK=
CAL-72 Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjC[nRHUUN3ME22MlQ2PDJ|IN88US=> M4TTdnNCVkeHUh?=
HCC1806 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZwOEG5N|Eh|ryP NXezUIo3W0GQR1XS
BCPAP NWC4OYNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojTTWM2OD15LkKxO|Y1KM7:TR?= MVTTRW5ITVJ?
LB2241-RCC NXPFPGlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTdwM{[5NFch|ryP NWfIe4ZNW0GQR1XS
COLO-741 M2KyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fWO2lEPTB;OD6wNVY4QSEQvF2= NYjac3BZW0GQR1XS
HSC-3 NVv2fm4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XiSWlEPTB;OD6wO|A3QCEQvF2= NFHie45USU6JRWK=
SW982 NWHWdGFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPaXWRKSzVyPUiuOFE2OTZizszN MkD6V2FPT0WU
GCT M1nz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnnTlFKSzVyPUiuO|U{OTRizszN M3qyXXNCVkeHUh?=
KY821 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfRSW5PUUN3ME25MlA2OTd6IN88US=> MoLwV2FPT0WU
JVM-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz1TWM2OD17LkW2PVk6KM7:TR?= M3rodXNCVkeHUh?=
RS4-11 M4TkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG3TWM2OD17Lk[wOFgh|ryP NGLjeXpUSU6JRWK=
VA-ES-BJ NF\2cVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFyLkCxOFkh|ryP NXXpO2hCW0GQR1XS
A431 NHnkNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFyLkSyNVIh|ryP M{XoNHNCVkeHUh?=
LXF-289 M3r2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ae3lKSzVyPUGwMlQ2QCEQvF2= MkXOV2FPT0WU
SK-MEL-24 NVK2RWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\2XGlEPTB;MUCuPFI4PCEQvF2= MUTTRW5ITVJ?
NOS-1 M1rQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHpOHVKSzVyPUGwMlg1PzJizszN MnPZV2FPT0WU
KNS-62 M3nmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPSSWpKSzVyPUGxMlI1ODRizszN NFrZSotUSU6JRWK=
SK-HEP-1 NVu0coV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjMR4k4UUN3ME2xNU4{PTJ5IN88US=> NFfKNHJUSU6JRWK=
A3-KAW MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFzLkexO|gh|ryP M4rpVHNCVkeHUh?=
SK-LU-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLabHI3UUN3ME2xNk4zPjV3IN88US=> NYKzc3FRW0GQR1XS
TYK-nu NVzGVI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXTcohKSzVyPUGyMlM6OzJizszN MV;TRW5ITVJ?
NMC-G1 NGW0NVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LBU2lEPTB;MUKuOlA3OiEQvF2= MX3TRW5ITVJ?
BB65-RCC NGC1R3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLCN3pKSzVyPUGyMlcyPjlizszN MUTTRW5ITVJ?
QIMR-WIL NHW3WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTZTWM2OD1zMj64PFM{KM7:TR?= MYjTRW5ITVJ?
D-566MG NUXne25zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfKPGJKSzVyPUGzMlk2PzZizszN M4rKTnNCVkeHUh?=
KYSE-140 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T1bWlEPTB;MUSuNFc2OyEQvF2= MW\TRW5ITVJ?
SCC-4 NGq5WlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\tNZdKSzVyPUG0MlM{PTlizszN NF3PVnBUSU6JRWK=
U251 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\HTYhKSzVyPUG0Mlg1QTJizszN MnPsV2FPT0WU
D-542MG NV7ufIo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF2LkmyNlIh|ryP NUnrcmpRW0GQR1XS
LAMA-84 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELCclhKSzVyPUG0Mlk6OzJizszN M{PpZnNCVkeHUh?=
NCI-H720 NVnKSHc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF3LkK2PFQh|ryP NV\uNnV2W0GQR1XS
DEL NVjUPIo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn2cmRKSzVyPUG1MlQzQTNizszN MVLTRW5ITVJ?
SBC-1 NXjUfllFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3yTWM2OD1zNT60N|A2KM7:TR?= MV\TRW5ITVJ?
ECC10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjUXoJvUUN3ME2xOU41PDV6IN88US=> NWnmdWRlW0GQR1XS
Daoy MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLLTWM2OD1zNT63OlE3KM7:TR?= M2jSbXNCVkeHUh?=
SCH NEjjTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF3Lke4N|Uh|ryP NXHQSXFIW0GQR1XS
MZ2-MEL M2nKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe0empKSzVyPUG2MlA3PDZizszN MXjTRW5ITVJ?
CAL-12T M{DNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF4LkS4OlIh|ryP MVzTRW5ITVJ?
KE-37 M4HDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjCcIxKSzVyPUG2MlgyODdizszN NETO[nJUSU6JRWK=
LS-411N NIfUSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TyVWlEPTB;MUeuNVE5KM7:TR?= NF\mSm1USU6JRWK=
NCI-H2228 NUm1SoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP4XYlKSzVyPUG3MlMxPzFizszN MULTRW5ITVJ?
SK-MEL-2 NFHyNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7vTWM2OD1zNz60PVY2KM7:TR?= MnGyV2FPT0WU
HN MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fqNmlEPTB;MUeuO|I1QCEQvF2= NX:wWXpVW0GQR1XS
NCI-H1648 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nGU2lEPTB;MUeuPFE5KM7:TR?= M{jVeXNCVkeHUh?=
IA-LM MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF6LkOxO|Ih|ryP NXTBN5JoW0GQR1XS
EW-13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL1TWM2OD1zOD61O|A5KM7:TR?= MXvTRW5ITVJ?
YKG-1 NV34ZoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGwU2xqUUN3ME2xPU42PzFzIN88US=> NGTDXZFUSU6JRWK=
KNS-81-FD MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i1W2lEPTB;MUmuOVg2QCEQvF2= Mo\jV2FPT0WU
23132-87 NU\GTZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\HTHdEUUN3ME2xPU44PjR{IN88US=> NH3pOlJUSU6JRWK=
NUGC-3 M{fad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\5TWM2OD1zOT65PFg4KM7:TR?= NUHKR3VFW0GQR1XS
5637 NFnOSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJyLkC0O|gh|ryP NH\3[ZdUSU6JRWK=
NCI-H1755 NELkU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PtfmlEPTB;MkCuOFc3PCEQvF2= NHPKcopUSU6JRWK=
RH-18 Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjGSVZKUUN3ME2yNE42PzR6IN88US=> MmnQV2FPT0WU
RXF393 M3jWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLJWJVKSzVyPUKwMlY4PTZizszN M4eyZ3NCVkeHUh?=
LU-134-A NVmxeoF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjBXFJKSzVyPUKwMlcxPTZizszN M1LoXXNCVkeHUh?=
TE-12 M3;VO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LpWmlEPTB;MkCuO|IxOSEQvF2= M2fqNXNCVkeHUh?=
MOLT-4 NFLjXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJzLkG5NVUh|ryP MlXnV2FPT0WU
IGR-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjxblFKSzVyPUKxMlM4QTZizszN M2PCfHNCVkeHUh?=
HOP-92 NFXYfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrhTWM2OD1{MT60PVg4KM7:TR?= NHXoVppUSU6JRWK=
SK-MES-1 NHr0UFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJzLkezPFEh|ryP NYnMZVcxW0GQR1XS
LU-65 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13XcWlEPTB;MkGuPFYzPCEQvF2= M2TGbHNCVkeHUh?=
MS-1 NEPOZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fUVGlEPTB;MkKuNVIxOyEQvF2= MWfTRW5ITVJ?
LoVo MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ{LkK0OEDPxE1? MUnTRW5ITVJ?
A704 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJ{LkWxOVUh|ryP NWO3OHYyW0GQR1XS
HT-1376 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInVXWRKSzVyPUKyMlYxPTlizszN MljPV2FPT0WU
IST-MEL1 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDxTWM2OD1{Mj62O|UyKM7:TR?= MYPTRW5ITVJ?
Ramos-2G6-4C10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDUTWM2OD1{Mj63N|Y3KM7:TR?= M{PUXnNCVkeHUh?=
T47D M37j[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHlR2ZKSzVyPUKyMlc6PzlizszN MnjBV2FPT0WU
HT-1197 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXWTWM2OD1{Mz6wPFE4KM7:TR?= NYm5O2JEW0GQR1XS
LB2518-MEL MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\LV2tKSzVyPUKzMlY1OTJizszN MoXzV2FPT0WU
J-RT3-T3-5 NHXJOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnyUXFoUUN3ME2yOE44PTl3IN88US=> MVLTRW5ITVJ?
SK-NEP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknTTWM2OD1{ND64O|Q1KM7:TR?= NUD5[2U{W0GQR1XS
NCI-H526 NX\vS29pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC1bZBKSzVyPUK1MlAxOjNizszN NYK3TYdiW0GQR1XS
IST-SL1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLHNWtKSzVyPUK1MlI4PTFizszN MW\TRW5ITVJ?
HH NWrjO5luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPodYZKSzVyPUK1MlMyQTJizszN MX;TRW5ITVJ?
NCI-H82 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PDZmlEPTB;MkWuPVM5KM7:TR?= M3fXb3NCVkeHUh?=
SNU-449 NIjIVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTLTWM2OD1{Nz6yNFE5KM7:TR?= M1LlUXNCVkeHUh?=
COR-L23 M3Plc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PVfmlEPTB;MkeuNlgyOyEQvF2= MWjTRW5ITVJ?
LOXIMVI MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXoTWM2OD1{Nz6zOlgh|ryP MmDkV2FPT0WU
GR-ST NEm3WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlruTWM2OD1{Nz62O|A3KM7:TR?= M1PTRXNCVkeHUh?=
NCI-SNU-1 NGn0No5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnHXHVKSzVyPUK3Mlk1PCEQvF2= NFPiRppUSU6JRWK=
ALL-PO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm1SW5nUUN3ME2yPE4yPjB2IN88US=> NV20Z4pWW0GQR1XS
ML-2 NGXLTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fDVGlEPTB;MkiuNlgyPCEQvF2= NHXLOG9USU6JRWK=
HOP-62 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP0R4VKSzVyPUK4MlcyOyEQvF2= NHrNdJVUSU6JRWK=
EGI-1 M4POPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\wSoNKSzVyPUK4Mlg5PDVizszN MlLyV2FPT0WU
TCCSUP NWXHXJhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TWdmlEPTB;MkiuPVI4OiEQvF2= MWTTRW5ITVJ?
LB996-RCC MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHKTWM2OD1{OT61OlgzKM7:TR?= MXfTRW5ITVJ?
LCLC-97TM1 NWXkfG9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXpSWlKSzVyPUOyMlE6PjRizszN MW\TRW5ITVJ?
NCI-H1304 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPwTWM2OD1|Mj6zN|AyKM7:TR?= M3;4V3NCVkeHUh?=
KP-N-YS NI\LcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPwVJJUUUN3ME2zNk42QTd|IN88US=> M1KyeXNCVkeHUh?=
NCI-H1770 NHjRN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN|LkG2OFgh|ryP MYTTRW5ITVJ?
EM-2 M2\SOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPHTWM2OD1|Mz62OVA1KM7:TR?= NEPMeJdUSU6JRWK=
ChaGo-K-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm0TWM2OD1|Mz63NlM3KM7:TR?= M2Hjb3NCVkeHUh?=
ACHN NVXy[FFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PYcWlEPTB;M{OuPFM5PSEQvF2= NGW0bplUSU6JRWK=
MN-60 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XX[WlEPTB;M{OuPFU1PCEQvF2= NYL5[XF2W0GQR1XS
EW-18 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTsTWM2OD1|Mz64PVcyKM7:TR?= MXTTRW5ITVJ?
KGN NW\HflVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPUe|dvUUN3ME2zOU44Ojl{IN88US=> M3y5NnNCVkeHUh?=
U031 NVjhRYpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XSVmlEPTB;M{WuPFE{OiEQvF2= NVXXR4JqW0GQR1XS
HMV-II NG\IWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfQSYg4UUN3ME2zOk4xPzd2IN88US=> M3ra[HNCVkeHUh?=
L-363 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy4dVVTUUN3ME2zO{43PDV3IN88US=> NIP0Z5NUSU6JRWK=
NCI-H1155 M3PM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzqbphKSzVyPUO4MlAxOTVizszN MVzTRW5ITVJ?
NCI-H1793 NXf0VIdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vyV2lEPTB;M{iuNVAzPiEQvF2= NWm0RnhlW0GQR1XS
P30-OHK M2q0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN6LkGzN|Ih|ryP M{jmVXNCVkeHUh?=
AN3-CA MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjFflVKSzVyPUO4MlE3OTVizszN NIDjXFJUSU6JRWK=
UACC-257 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnjTWM2OD1|OD63PUDPxE1? MX7TRW5ITVJ?
MCF7 NUK2ToRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\VNGZKSzVyPUO5Mlg3OjlizszN MXHTRW5ITVJ?
KP-N-YN Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XIZWlEPTB;NECuOFI5PSEQvF2= NW\ZWJhYW0GQR1XS
T98G MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PNdGlEPTB;NECuOFk2PyEQvF2= Ml\TV2FPT0WU
HGC-27 M1XWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPaTWM2OD12Mz6yO|Qh|ryP MUfTRW5ITVJ?
NCI-H1092 M3TYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLlTWM2OD12Mz6yPFk2KM7:TR?= MlPKV2FPT0WU
KARPAS-299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjZTWM2OD12Mz6zNFcyKM7:TR?= MlnwV2FPT0WU
LB1047-RCC MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP6So52UUN3ME20OE46QTV7IN88US=> MXjTRW5ITVJ?
786-0 NGDJc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33zW2lEPTB;NEWuOlUh|ryP M4jTRXNCVkeHUh?=
HCC2157 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR4LkCzOVkh|ryP MnzaV2FPT0WU
NY M1TRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR4LkG3O|gh|ryP MoLKV2FPT0WU
EFM-19 NVjpeo81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\uTWM2OD12Nj63OVM{KM7:TR?= MkXjV2FPT0WU
EW-16 M{KzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR4Lke4NFYh|ryP NXTEOIxkW0GQR1XS
UM-UC-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj0[VJKSzVyPUS2MlgxPTlizszN NIfYflVUSU6JRWK=
HT-29 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTR5Lki3PVIh|ryP NVHzNJdUW0GQR1XS
LN-405 M1H0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR6LkC4Nlch|ryP MX\TRW5ITVJ?
NCI-H727 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPERWZKSzVyPUS4Mlc4OjZizszN NYTXTpZpW0GQR1XS
D-502MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTR6Lkm2O|Yh|ryP NX;GeFF5W0GQR1XS
GMS-10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkixTWM2OD12OT6yPVc1KM7:TR?= M1z1ZnNCVkeHUh?=
MEL-JUSO M4\uTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO1RoFSUUN3ME20PU4{PDdizszN NYXZSmR3W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]

Protocol

Kinase Assay:[1]
+ Expand

In vitro Raf kinase activities:

The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:[1]
+ Expand
  • Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 mM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
  • Formulation: Suspended in vehicle (5% DMSO, 1% methylcellulose)
  • Dosages: 5, 20, or 100 mg/kg
  • Administration: Oral gavage once or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.83
Formula

C17H14ClF2N3O3S

CAS No. 918505-84-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What would you recommend to make working solution for intraperitoneal injection into mice?

  • Answer:

    PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Tags: buy PLX-4720 | PLX-4720 supplier | purchase PLX-4720 | PLX-4720 cost | PLX-4720 manufacturer | order PLX-4720 | PLX-4720 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID